[96a5a0]: / output / allTrials / identified / NCT01487720_identified.json

Download this file

323 lines (323 with data), 12.9 kB

  1
  2
  3
  4
  5
  6
  7
  8
  9
 10
 11
 12
 13
 14
 15
 16
 17
 18
 19
 20
 21
 22
 23
 24
 25
 26
 27
 28
 29
 30
 31
 32
 33
 34
 35
 36
 37
 38
 39
 40
 41
 42
 43
 44
 45
 46
 47
 48
 49
 50
 51
 52
 53
 54
 55
 56
 57
 58
 59
 60
 61
 62
 63
 64
 65
 66
 67
 68
 69
 70
 71
 72
 73
 74
 75
 76
 77
 78
 79
 80
 81
 82
 83
 84
 85
 86
 87
 88
 89
 90
 91
 92
 93
 94
 95
 96
 97
 98
 99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
{
"info": {
"nct_id": "NCT01487720",
"official_title": "A Prosepctive Phase II Study of Gemcitabine and Oxaliplatin in Combination With Prednisolone for the Treatment of Hormone Refracotry Metastatic Prostate Cancer Previously Treated With Docetaxel Regimen",
"inclusion_criteria": "* Histologically or cytologically confirmed adenocarcinoma of the prostate\n* Clinical or radiologic evidence of metastatic disease\n* Documented disease progression during hormone therapy (ADT plus antiandrogen) and no response to ADT withdrawal\n* Docetaxel-refractory disease defined as disease progression documented either during treatment of within 60 days after the cessation of treatment with docetaxel\n* Prior exposure to estramustine or mitoxantrone is allowed\n* KPS ≥ 60\n* No prior radioisotope therapy\n* No prior radiotherapy 25% or more of the bone marrow\n* No peripheral neuropathy grade 2 or worse\n* Adequate organ and bone marrow function\nHealthy volunteers allowed\nMust be MALE\nMust have minimum age of 18 Years",
"exclusion_criteria": "* Other tumor type than adenocarcinoma\n* Presence or history of CNS metastasis\n* Other serious illness or medical conditions",
"miscellaneous_criteria": ""
},
"inclusion_lines": [
{
"line": "* Histologically or cytologically confirmed adenocarcinoma of the prostate",
"criterions": [
{
"exact_snippets": "Histologically or cytologically confirmed adenocarcinoma of the prostate",
"criterion": "adenocarcinoma of the prostate",
"requirements": [
{
"requirement_type": "confirmation method",
"expected_value": [
"histologically",
"cytologically"
]
}
]
}
]
},
{
"line": "* Clinical or radiologic evidence of metastatic disease",
"criterions": [
{
"exact_snippets": "Clinical or radiologic evidence of metastatic disease",
"criterion": "metastatic disease",
"requirements": [
{
"requirement_type": "evidence",
"expected_value": [
"clinical",
"radiologic"
]
}
]
}
]
},
{
"line": "* Documented disease progression during hormone therapy (ADT plus antiandrogen) and no response to ADT withdrawal",
"criterions": [
{
"exact_snippets": "Documented disease progression during hormone therapy (ADT plus antiandrogen)",
"criterion": "disease progression during hormone therapy",
"requirements": [
{
"requirement_type": "documentation",
"expected_value": true
}
]
},
{
"exact_snippets": "no response to ADT withdrawal",
"criterion": "response to ADT withdrawal",
"requirements": [
{
"requirement_type": "response",
"expected_value": false
}
]
}
]
},
{
"line": "* Docetaxel-refractory disease defined as disease progression documented either during treatment of within 60 days after the cessation of treatment with docetaxel",
"criterions": [
{
"exact_snippets": "Docetaxel-refractory disease defined as disease progression documented either during treatment ... with docetaxel",
"criterion": "docetaxel-refractory disease",
"requirements": [
{
"requirement_type": "progression",
"expected_value": "documented either during treatment or within 60 days after cessation of treatment with docetaxel"
}
]
}
]
},
{
"line": "* Prior exposure to estramustine or mitoxantrone is allowed",
"criterions": [
{
"exact_snippets": "Prior exposure to estramustine",
"criterion": "prior exposure to estramustine",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
},
{
"exact_snippets": "Prior exposure to ... mitoxantrone",
"criterion": "prior exposure to mitoxantrone",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
}
]
}
]
},
{
"line": "* KPS ≥ 60",
"criterions": [
{
"exact_snippets": "KPS ≥ 60",
"criterion": "Karnofsky Performance Status (KPS)",
"requirements": [
{
"requirement_type": "score",
"expected_value": {
"operator": ">=",
"value": 60,
"unit": "N/A"
}
}
]
}
]
},
{
"line": "* No prior radioisotope therapy",
"criterions": [
{
"exact_snippets": "No prior radioisotope therapy",
"criterion": "prior radioisotope therapy",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
},
{
"line": "* No prior radiotherapy 25% or more of the bone marrow",
"criterions": [
{
"exact_snippets": "No prior radiotherapy 25% or more of the bone marrow",
"criterion": "prior radiotherapy to bone marrow",
"requirements": [
{
"requirement_type": "quantity",
"expected_value": {
"operator": "<",
"value": 25,
"unit": "%"
}
}
]
}
]
},
{
"line": "* No peripheral neuropathy grade 2 or worse",
"criterions": [
{
"exact_snippets": "No peripheral neuropathy grade 2 or worse",
"criterion": "peripheral neuropathy",
"requirements": [
{
"requirement_type": "severity",
"expected_value": {
"operator": "<",
"value": 2,
"unit": "grade"
}
}
]
}
]
},
{
"line": "* Adequate organ and bone marrow function",
"criterions": [
{
"exact_snippets": "Adequate organ ... function",
"criterion": "organ function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
},
{
"exact_snippets": "Adequate ... bone marrow function",
"criterion": "bone marrow function",
"requirements": [
{
"requirement_type": "adequacy",
"expected_value": true
}
]
}
]
},
{
"line": "Healthy volunteers allowed",
"criterions": [
{
"exact_snippets": "Healthy volunteers allowed",
"criterion": "volunteer health status",
"requirements": [
{
"requirement_type": "status",
"expected_value": "healthy"
}
]
}
]
},
{
"line": "Must be MALE",
"criterions": [
{
"exact_snippets": "Must be MALE",
"criterion": "gender",
"requirements": [
{
"requirement_type": "expected_value",
"expected_value": "male"
}
]
}
]
},
{
"line": "Must have minimum age of 18 Years",
"criterions": [
{
"exact_snippets": "minimum age of 18 Years",
"criterion": "age",
"requirements": [
{
"requirement_type": "minimum",
"expected_value": {
"operator": ">=",
"value": 18,
"unit": "Years"
}
}
]
}
]
}
],
"exclusion_lines": [
{
"line": "* Other tumor type than adenocarcinoma",
"criterions": [
{
"exact_snippets": "Other tumor type than adenocarcinoma",
"criterion": "tumor type",
"requirements": [
{
"requirement_type": "exclusion",
"expected_value": "adenocarcinoma"
}
]
}
]
},
{
"line": "* Presence or history of CNS metastasis",
"criterions": [
{
"exact_snippets": "Presence or history of CNS metastasis",
"criterion": "CNS metastasis",
"requirements": [
{
"requirement_type": "presence",
"expected_value": true
},
{
"requirement_type": "history",
"expected_value": true
}
]
}
]
},
{
"line": "* Other serious illness or medical conditions",
"criterions": [
{
"exact_snippets": "Other serious illness or medical conditions",
"criterion": "serious illness",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
},
{
"exact_snippets": "Other serious illness or medical conditions",
"criterion": "medical conditions",
"requirements": [
{
"requirement_type": "presence",
"expected_value": false
}
]
}
]
}
],
"miscellaneous_lines": [],
"failed_inclusion": [],
"failed_exclusion": [],
"failed_miscellaneous": []
}